Anticorps Polyclonal de lapin anti-c-Met (N-terminal)

• Phare
• Validé par KD/KO

c-Met (N-terminal) Polyclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications

3

N° de cat : 19971-1-AP

Synonymes

---

Galerie de données de validation

• 

  WB analysis of HeLa using 19971-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 19971-1-AP (c-Met (N-terminal) antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human colon using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human colon using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 40x lens).

---

Applications testées

• Résultats positifs en WB: cellules HeLa,
• Résultats positifs en IHC: tissu de cancer du sein humain, tissu de côlon humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000
• Immunohistochimie (IHC): IHC : 1:50-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 2 publications below
• IHC: See 1 publications below

Informations sur le produit

19971-1-AP cible c-Met (N-terminal) dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: met proto-oncogene (hepatocyte growth factor receptor)
• Masse moléculaire calculée: 156 kDa
• Poids moléculaire observé: 140 kDa, 50 kDa
• Numéro d’acquisition GenBank: NM_000245
• Symbole du gène: MET
• Identification du gène (NCBI): 4233
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). This antibody recognizes the N-term of c-Met.

Publications

Species	Application	Title
human	WB	Oncogene; A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.; Authors - F Yan
human	WB	Carcinogenesis; MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1.; Authors - Wu Jianmin J
mouse	IHC	Am J Pathol; PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.; Authors - Wen-Cheng Chung

Produits associés

PLXNB1 Polyclonal antibody

23795-1-AP

STAT3 Polyclonal antibody

10253-2-AP

PI3 Kinase p85 Alpha Monoclonal antibody

60225-1-Ig

c-SRC Polyclonal antibody

11097-1-AP

HER2/ErbB2 Monoclonal antibody

60311-1-Ig

EGFR-Specific Polyclonal antibody

18986-1-AP